A comprehensive review of interventions in the NOD mouse and implications for translation

被引:232
作者
Shoda, LKM
Young, DL
Ramanujan, S
Whiting, CC
Atkinson, MA
Bluestone, JA
Eisenbarth, GS
Mathis, D
Rossini, AA
Campbell, SE
Kahn, R
Kreuwel, HT
机构
[1] Entelos Inc, Foster City, CA 94404 USA
[2] Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA
[3] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA
[4] Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA
[5] Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Med, Joslin Diabet Ctr,Sect Immunol & Immunogenet, Boston, MA 02215 USA
[6] Univ Massachusetts, Sch Med, Diabet Div, Worcester, MA 01605 USA
[7] Amer Diabet Assoc, Alexandria, VA 22311 USA
关键词
D O I
10.1016/j.immuni.2005.08.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Type 1 diabetes (T1D) animal models such as the non-obese diabetic (NOD) mouse have improved our understanding of disease pathophysiology, but many candidate therapeutics identified therein have failed to prevent/cure human disease. We have performed a comprehensive evaluation of disease-modifying agents tested in the NOD mouse based on treatment timing, duration, study length, and efficacy. Interestingly, some popular tenets regarding NOD interventions were not confirmed: all treatments do not prevent disease, treatment dose and timing strongly influence efficacy, and several therapies have successfully treated overtly diabetic mice. The analysis provides a unique perspective on NOD interventions and suggests that the response of this model to therapeutic interventions can be a useful predictor of the human response as long as careful consideration is given to treatment dose, timing, and protocols; more thorough investigation of these parameters should improve clinical translation.
引用
收藏
页码:115 / 126
页数:12
相关论文
共 114 条
[91]   Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes [J].
Slavin, AJ ;
Maron, R ;
Weiner, HL .
INTERNATIONAL IMMUNOLOGY, 2001, 13 (06) :825-833
[92]   Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice [J].
Song, S ;
Goudy, K ;
Campbell-Thompson, M ;
Wasserfall, C ;
Scott-Jorgensen, M ;
Wang, J ;
Tang, Q ;
Crawford, JM ;
Ellis, TM ;
Atkinson, MA ;
Flotte, TR .
GENE THERAPY, 2004, 11 (02) :181-186
[93]  
Takahashi M, 2000, RADIAT RES, V154, P680, DOI 10.1667/0033-7587(2000)154[0680:POTIDB]2.0.CO
[94]  
2
[95]   In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes [J].
Tang, QZ ;
Henriksen, KJ ;
Bi, MY ;
Finger, EB ;
Szot, G ;
Ye, JQ ;
Masteller, EL ;
McDevitt, H ;
Bonyhadi, M ;
Bluestone, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (11) :1455-1465
[96]   Cutting edge:: CD28 controls peripheral homeostasis of CD4+CD25+ [J].
Tang, QZ ;
Henriksen, KJ ;
Boden, EK ;
Tooley, AJ ;
Ye, JQ ;
Subudhi, SK ;
Zheng, XX ;
Strom, TB ;
Bluestone, JA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (07) :3348-3352
[97]  
THIVOLET C, 1991, J IMMUNOL, V146, P85
[98]   Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice [J].
Tominaga, Y ;
Nagata, M ;
Yasuda, H ;
Okamoto, N ;
Arisawa, K ;
Moriyama, H ;
Miki, M ;
Yokono, K ;
Kasuga, M .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1998, 86 (02) :209-218
[99]   Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes [J].
Trembleau, S ;
Penna, G ;
Gregori, S ;
Gately, MK ;
Adorini, L .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (09) :2330-2339
[100]   Early Th1 response in unprimed nonobese diabetic mice to the tyrosine phosphatase-like insulinoma-associated protein 2, an autoantigen in type 1 diabetes [J].
Trembleau, S ;
Penna, G ;
Gregori, S ;
Magistrelli, G ;
Isacchi, A ;
Adorini, L .
JOURNAL OF IMMUNOLOGY, 2000, 165 (12) :6748-6755